Introduction to InnoThyroGen at ESPT2025

From 5 to 8 November 2025, the city of Rotterdam hosted the 8th International Congress of the European Society for Pharmacogenomics and Personalised Therapy (ESPT2025).
The congress brought together more than 480 experts, including scientists, healthcare professionals, pharmacists, clinicians, students, regulators and industry representatives.
During this important scientific event, Dr. Branka Zukić from IMGGE represented the InnoThyroGen project and contributed to raising its visibility across the European pharmacogenomics community.

About the Event: InnoThyroGen at ESPT2025

ESPT2025 focused on both current developments and future directions in pharmacogenomics and personalised medicine.
The programme covered a wide range of topics, including clinical implementation, psychiatry, oncology, cardiology, diabetes, pediatrics, transplantation, regulatory challenges, liquid biopsy, and decision-support tools.
In addition, the congress highlighted innovations in genotyping technologies and national initiatives that support personalised therapy.

Because of its multidisciplinary structure, the event created an ideal environment for collaboration between basic, clinical and translational researchers. Furthermore, it helped connect scientists with regulators and industry stakeholders.

IMGGE Presents InnoThyroGen at ESPT2025

During the congress, Dr. Branka Zukić presented a poster titled:
“Population Pharmacogenomics for Clinical Implementation in Serbia: Insights from the PharmGenHUB Study.”

Her presentation offered valuable insights into population-level pharmacogenomics and its potential application in clinical practice.
Furthermore, she used the opportunity to introduce participants to the goals, activities and scientific direction of the InnoThyroGen project.
As a result, the project reached a highly relevant audience of experts working in fields closely linked to personalised medicine and genomic research.

Impact of InnoThyroGen at ESPT2025

The event delivered several important outcomes for the project:

• More than 480 international participants learned about InnoThyroGen.
• Direct discussions increased awareness of the project’s aims and future activities.
• Stakeholders gained a clearer understanding of the project’s contribution to personalised medicine.
• Networking strengthened links between InnoThyroGen and leading European pharmacogenomics researchers.
• The congress supported wider dissemination of InnoThyroGen across scientific, clinical and regulatory communities.

Consequently, InnoThyroGen at ESPT2025 significantly improved project visibility and reinforced its relevance in Europe’s personalised medicine ecosystem.

Conclusion

ESPT2025 proved to be a valuable platform for scientific exchange and collaboration.
Through active participation, Dr. Zukić expanded awareness of the project and opened new opportunities for dialogue across clinical, academic and regulatory sectors.
In this way, InnoThyroGen at ESPT2025 supports continued progress in personalised therapy and strengthens the project’s role within the European pharmacogenomics landscape.

Stay Tuned

Stay tuned for more updates from upcoming scientific events.
Follow InnoThyroGen on LinkedIn, X (Twitter), Facebook and Instagram for the latest news, activities and research insights.